Refrigid cell therapy: New glimmer of hope for brain infections!

Refrigid cell therapy: New glimmer of hope for brain infections!

autoimmune brain inflammation are a secret masonry of neurology, and especially the anti-nmda receptor encephalitis hits many people unprepared. This rare, but difficult to get disease means that the immune system incorrectly attacks its own nerve cells and sometimes causes dramatic psychiatric symptoms. If you don't get help quickly, you usually have bad cards. After about twelve years, in which many medical mysteries have been deciphered around this disease, we are now facing a real turn in treatment.

Researchers of Charité have developed a new treatment approach. The body's immune cells are to be equipped with a chimeric autoantibody receptor (Caar) . This makes it possible to track down and switch off the disease -causing cells, while the rest of the immune system continues to perceive its protective functions.

The way to the new therapy

In the heart of this project, the construction of a GMP-compliant gene ferry is based on special viruses and enables the CAAR-Erbut to bring in therapeutic cells. A funding of around 1.5 million euros ensures that implementation progresses. The planned production of the NMDAR-CAAR-T cells in the Berlin Center for Advanced Therapies (Becat) is to start in the next or next year, followed by a first clinical phase-I study to use these cells in the treatment of NMDAR-Encephalitis. Interestingly, this study is carried out in cooperation with the clinical research group Becausey.

Anti-NMDA receptor encephalitis not only represents a medical challenge, but also has extensive effects on the lives of those affected by their symptoms-such as memory disorders, epileptic seizures and consciousness disorders. This is affected by this annually 200 to 300 people in Germany, with a striking relationship between women to men from around 8: 2.

a step into the future

The diagnosis of the disease is also not a sugar. It is often a challenge to distinguish the symptoms of primary psychiatric disorders. This is where research comes into play: animal models show the complex mechanisms of the disease and could help develop new treatment methods. According to PubMed it is mainly auto antibodies that play a role and represent an important diagnostic marker. Unfortunately there are hardly any prognostic biomarkers who go beyond the clinical assessment.

In the long term, the new therapy not only hopes for a decline in symptoms, but also the prevention of relapses and the restoration of the quality of life for the patient: inside. According to the researchers, the one-time administration of the reprogrammed T cells could even be a healing of the disease-a glimmer of hope that many affected people are waiting for.

As we see, the project that started in the laboratory six years ago has now started on the way to practical application. It remains exciting to follow how this new approach can not only treat NMDA receptor encephalitis, but may also be used to other autoimmune encephalopathies. The team around Professor Harald Prüß works with high pressure on this promising treatment - a real sign of progress in neurology.

If you want to learn more about the fascinating aspects of this research, find more information on the website of the Charité href = "https://www.dzne.de/aktuelles/pressemitteilungen/presse/neuigartiger--seatset-verpragicht-bereutende-be-der-beitung-autoimmuner-hirn-entzuendungen/"> dzne .